RecruitingNCT06206681
Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
Sponsor
Sun Yat-sen University
Enrollment
1,000 participants
Start Date
Nov 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to assess the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision in the treatment of eyelid tumors, including xanthelasma, pigmented nevi, keratoses, and so on.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This study evaluates whether a type of CO2 laser treatment (called UltraPulse) is safe and effective for removing growths on the eyelids, such as fatty deposits (xanthelasma), moles, warts, and other benign lesions.
**You may be eligible if...**
- You have been clinically diagnosed with benign eyelid growths such as xanthelasma, pigmented moles, or keratoses
- You have no history of light sensitivity, or bleeding/clotting disorders
- You are willing to attend scheduled follow-up appointments
**You may NOT be eligible if...**
- You have an active infection near the treatment area
- You have a history of abnormal scarring (keloids)
- You are pregnant or breastfeeding
- You have used blood-thinning medications recently
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREUltra-pulsed Carbon Dioxide Laser
Excision of eyelid lesion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06206681